Stocktoria
MADRIGAL PHARMACEUTICALS, INC. MDGL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2007-02-06
MADRIGAL PHARMACEUTICALS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -31.3% | -276.4% | — | — | — |
| Net margin | -30.1% | -258.6% | — | — | — |
| FCF margin | -19.8% | -253.7% | — | — | — |
| Return on assets | -22.9% | -44.7% | -58.3% | -81.5% | -88.5% |
| Return on equity | -47.8% | -61.8% | -92.2% | -149.6% | -123.3% |
| Debt / equity | 0.56× | 0.16× | 0.28× | 0.35× | 0.00× |
| Current ratio | 4.01 | 6.10 | 5.38 | 3.12 | 3.54 |
| Revenue growth | 432.1% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001157601 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.